Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STICK trial of tucatinib and osimertinib pharmacokinetics in primary and metastatic brain tumors
NL-OMON59981Phase 1Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-arm trial of tucatinib and osimertinib in breast cancer, non-small cell lung cancer (NSCLC), glioblastoma (GBM) and 1 more, sponsored by Amsterdam University Medical Center. Primary endpoint: Primary endpoint(s). Planned start May 2026; status: not yet recruiting.
02
Drugs
tucatinibosimertinib
03
Conditions
breast cancernon-small cell lung cancer (NSCLC)glioblastoma (GBM)brain neoplasm
Beyond the preview
Go deeper on NL-OMON59981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59981.